RxDoctor Payments Data

Adam Zivin, MD

Cardiovascular Disease · Bellevue, WANPI 1578670154

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (39.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Boston Scientific at 26.8% of the total. Among cardiovascular disease clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$22,681in general payments, 2019–2025

Across 196 payments — averaging $115.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$6K
  • Philips North America LLC$4K
  • Atricure, Inc.$4K
  • Medtronic$3K
  • Abbott$2K
  • Siemens Medical Solutions USA, Inc.$1K
  • plus $2K from 7 others
$2,079in research payments, 2019–2025

Across 1 payment — averaging $2079.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$2K

What the payments were for

  • Consulting fees$5,76025%
  • Travel & lodging$8,93339%
  • Food & beverage$7,98835%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,681 in reported general payments places this provider in the 90th percentile of 370 cardiovascular disease providers in Washington.

See all cardiovascular disease providers in Washington

Medicare billing

Part B allowed, 2024
$341,213
Medicare patients
1,332
Services billed
4,700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban318$381,816
XareltoRivaroxaban154$160,710
MultaqDronedarone Hcl52$67,876
Dofetilide125$22,547
Flecainide Acetate160$3,873
SotalolSotalol Hcl192$3,681
Metoprolol Succinate227$3,201
Verapamil ErVerapamil Hcl112$2,088
Amiodarone Hcl113$1,678
Diltiazem 24hr Er (Cd)Diltiazem Hcl68$1,526
Propafenone Hcl ErPropafenone Hcl17$1,067
Digoxin34$899
Diltiazem 24hr ErDiltiazem Hcl14$625
Potassium Chloride36$439
Carvedilol32$382

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Bellevue

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →